Isoniazid and Drug-Induced Lupus: A Rare Immune Reaction

**Ms, Asavari Vilas Chavan\*, Mr. Sandip V. Jadhav Dr. Vijaysinh Sable, Dr. Rani M. Metre,**

 Author, Assistant Professor, Associate Professor , Associate Professor,

Department Of Pharmacology

Lokmangal College Of Pharmacy Wadala, Solapur ,Maharashtra, India.

# abstract

# Isoniazid (INH), a first-line antituberculosis medication, has been widely used for the treatment and prevention of tuberculosis. Despite its efficacy, INH is associated with various adverse effects, among which drug-induced lupus erythematosus (DILE) is a rare but notable immune-mediated reaction. DILE presents with clinical features similar to idiopathic systemic lupus erythematosus, including arthralgia, myalgia, fever, and serositis, but typically lacks major organ involvement. This abstract reviews the incidence, pathogenesis, clinical manifestations, diagnosis, and management of INH-induced lupus. The pathogenesis involves the induction of autoantibodies, particularly antihistone antibodies, triggered by the drug in genetically predisposed individuals. Diagnosis is primarily clinical, supported by serological tests, and the resolution of symptoms upon discontinuation of the offending agent. Management involves cessation of INH and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids for symptomatic relief. Awareness and early recognition of this rare adverse effect are crucial for prompt and effective management, minimizing patient morbidity.

#  Keywords: Isoniazid, Drug-Induced Lupus, Erythematosus (DILE), Autoantibodies, Antituberculosis Therapy.

# Introduction

Drug-induced lupus erythematosus (DILE) is a rare yet significant adverse event associated with various medications. Among these, isoniazid, a front-line drug used in the treatment of tuberculosis, has gained particular attention due to its potential to trigger DILE. The importance of this topic lies in the need to raise awareness among healthcare professionals and the general public about the risks and implications of drug-induced lupus, especially in the context of isoniazid use (1). Isoniazid is a cornerstone in tuberculosis treatment programs worldwide, serving as an integral component of tuberculosis control efforts. However, the occurrence of DILE with isoniazid, while infrequent, has raised concerns regarding the safety and management of this widely used medication. Understanding the connection between isoniazid and DILE is crucial because of the drug's continued use in the treatment of a disease that remains a global public health concern (2). Moreover, since DILE can present with symptoms similar to systemic lupus erythematosus (SLE), early diagnosis and proper management are essential to prevent unnecessary suffering and complications in patients (3). This review aims to shed light on the mechanisms, clinical presentation, diagnosis, management, and prevention of isoniazid-induced lupus, providing valuable insights for healthcare practitioners, researchers, and patients.

The use of isoniazid, a potent and vital antimicrobial agent, in the treatment of tuberculosis has been a cornerstone of tuberculosis control programs for decades. However, a growing body of evidence has revealed an intriguing and potentially problematic association between isoniazid and drug-induced lupus erythematosus (DILE). While DILE is a rare occurrence, it presents a complex challenge to clinicians and patients alike (4). The specific problem is the development of lupus-like symptoms in individuals treated with isoniazid, which can sometimes lead to misdiagnosis, unnecessary interventions, and delays in appropriate care.One of the core issues is the similarity of symptoms between DILE and systemic lupus erythematosus (SLE), a chronic autoimmune disease. Patients experiencing drug-induced lupus may present with arthralgia, skin rashes, fever, and other symptoms that are common to both conditions (5). This often necessitates a comprehensive evaluation to distinguish between the two. The problem becomes more pronounced in areas with high tuberculosis prevalence, where isoniazid use is widespread. Clinicians, sometimes unfamiliar with the possibility of DILE, may miss the connection, potentially leading to prolonged suffering for the patient (6). This review aims to address this issue by thoroughly exploring the occurrence of drug- induced lupus with isoniazid, including its clinical presentation, potential mechanisms, diagnostic challenges, and management strategies. A better understanding of this problem is crucial in providing timely and accurate care to patients, improving their quality of life, and ensuring the appropriate use of isoniazid in tuberculosis treatment programs.

The primary objective of this review is to conduct a comprehensive exploration of the intricate relationship between isoniazid and drug-induced lupus erythematosus (DILE). Despite its rarity, this association is of significant clinical importance, deserving of in-depth analysis. The review takes a multifaceted approach, aiming to dissect various dimensions of DILE linked to isoniazid. It encompasses an investigation into the mechanisms underpinning the development of lupus-like symptoms triggered by isoniazid. These mechanisms may involve immune responses, genetic factors, or interactions with other medications, and their elucidation is vital for a comprehensive

understanding of this unique pharmacological phenomenon. Moreover, understanding the clinical presentation of isoniazid-induced lupus is of paramount importance (7). The review will delve into the symptoms and signs that affected patients may exhibit, as well as the crucial distinctions between DILE and systemic lupus erythematosus (SLE). Real-world case studies will be examined to provide insights into the practical manifestations of this condition. Accurate diagnosis of DILE is another significant challenge to address. The review will discuss the diagnostic criteria and tests that help differentiate isoniazid-induced lupus from other autoimmune diseases and SLE, ensuring that healthcare professionals can make precise and timely assessments. Effective management of patients diagnosed with isoniazid-induced lupus is critical, and the review will investigate the strategies and treatment options available to alleviate symptoms and improve their overall well-being (8). It will also explore the possibility of discontinuing isoniazid and transitioning to alternative therapies. Finally, prevention is a vital aspect of this review. The exploration will encompass strategies to prevent the occurrence of DILE in patients undergoing isoniazid treatment. Screening and monitoring recommendations will be discussed, as well as advocating for patient education and awareness regarding this rare but significant adverse event (9). The comprehensive examination in this review aims to provide valuable insights for healthcare practitioners, researchers, and patients. Ultimately, it aims to contribute to improved patient care, informed decision-making, and safer medication practices in the context of isoniazid use.

This review holds significant importance within the fields of pharmacology and healthcare for several compelling reasons. Firstly, the intricate relationship between isoniazid and drug-induced lupus erythematosus (DILE) presents a unique and rare pharmacological phenomenon that warrants in-depth exploration. By comprehensively dissecting the mechanisms underlying the development of DILE in response to isoniazid, healthcare practitioners and pharmacologists gain a better understanding of how medications can induce autoimmune responses (10). A deepened comprehension of these mechanisms not only helps in recognizing isoniazid-induced lupus but also informs the broader field of drug-induced autoimmune disorders. Secondly, the clinical presentation of isoniazid-induced lupus closely mimics systemic lupus erythematosus (SLE), posing a diagnostic challenge (11). The review's emphasis on the clinical presentation of this condition has a direct impact on healthcare practice. Accurate diagnosis is essential for appropriate patient management. By distinguishing the nuanced differences in symptoms, healthcare practitioners can avoid misdiagnoses and unnecessary treatments, thereby improving patient care and reducing healthcare costs. Furthermore, the diagnostic challenges surrounding DILE associated with isoniazid are also of significance in the context of healthcare (12). The review delves into the diagnostic criteria and tests that can differentiate isoniazid-induced lupus from other autoimmune diseases, streamlining the diagnostic process. These insights have practical implications in the clinical setting, ensuring timely and accurate assessments that facilitate effective patient care. The management of patients diagnosed with isoniazid-induced lupus is yet another aspect of great importance. Effective management strategies have the potential to alleviate patient suffering, improve their quality of life, and avoid complications (13). By examining and presenting these strategies, the review offers practical guidance to healthcare practitioners, helping them navigate the challenges posed by this condition (14). Lastly, the review's exploration of prevention strategies aligns with the broader healthcare goals of enhancing patient safety and minimizing adverse drug events. This aspect has far-reaching implications not only for isoniazid but for the general principles of preventing drug-induced autoimmune reactions.

In conclusion, the significance of this review in the fields of pharmacology and healthcare lies in its contribution to the understanding of rare but clinically important pharmacological phenomena, its direct impact on patient care through improved diagnosis and management, and its alignment with broader healthcare objectives of drug safety and patient well-being.

# Historical Background

The historical context of isoniazid's emergence as a critical antimicrobial agent for tuberculosis treatment is integral to understanding the significance of its association with drug-induced lupus. Isoniazid, or INH, made its debut in the mid-20th century as a groundbreaking pharmacological weapon against tuberculosis. The drug was discovered by Selman Waksman, a renowned American microbiologist who was awarded the Nobel Prize in Physiology or Medicine for his work on antibiotics, including the discovery of streptomycin, another pivotal tuberculosis treatment (15). Isoniazid, initially known as "isonicotinic acid hydrazide," exhibited potent antitubercular properties and soon became an integral component of tuberculosis control programs globally. Its efficacy in eradicating Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, revolutionized the treatment of this infectious disease. The introduction of isoniazid marked a turning point in the fight against tuberculosis, significantly reducing mortality rates and enabling the effective management of tuberculosis cases (16). This historical background underscores the importance of isoniazid in public health, as it continues to be a primary drug in the treatment of tuberculosis. However, alongside its remarkable efficacy, isoniazid's association with drug-induced lupus is a rare but notable concern that warrants exploration in the context of its rich history in tuberculosis treatment (17).

The historical backdrop of drug-induced lupus erythematosus (DILE) and its intriguing association with isoniazid traces back to the mid-20th century, coinciding with the early use of this antitubercular medication (18). Reports of drug-induced lupus have been documented since the 1940s, with isoniazid emerging as one of the medications linked to this condition. One of the earliest documented cases was reported in 1952 by Christiansen and Weigand, who observed lupus-like symptoms in patients taking isoniazid for tuberculosis treatment. Subsequently, in the 1960s, several studies and case reports shed light on the connection between isoniazid and drug-induced lupus (19). These early reports highlighted the appearance of symptoms such as arthralgia, skin rashes, and fever, closely resembling those of systemic lupus erythematosus (SLE), in patients treated with isoniazid. The similarities between the two conditions often led to diagnostic challenges, with some patients being misdiagnosed with SLE (20). These early observations marked the inception of a scientific exploration into the unique phenomenon of DILE linked to isoniazid. Researchers and healthcare professionals began to recognize the need for a better understanding of the condition's mechanisms, clinical presentation, diagnosis, and management (21). This historical context serves as a foundation for the ongoing exploration of the relationship between isoniazid and drug-induced lupus, a rare but noteworthy adverse event with implications for both tuberculosis treatment and autoimmune disease management.

# Isoniazid and Drug-Induced Lupus: Mechanisms

Understanding the mechanisms of isoniazid action in the body is fundamental to exploring its potential role in drug-induced lupus erythematosus (DILE). Isoniazid, or INH, is a first-line antimycobacterial agent used in the treatment of tuberculosis (22). Its primary mode of action is to disrupt the synthesis of mycolic acids, a critical component of the mycobacterial cell wall. By inhibiting the enzyme enoyl-acyl carrier protein reductase, also known as InhA, isoniazid interferes with mycolic acid biosynthesis, weakening the structural integrity of the tuberculosis bacterium (23). Moreover, isoniazid is converted into its active form, isonicotinoyl-NAD, within the bacterial cell. This active metabolite interacts with an enzyme called KatG, leading to the production of reactive oxygen species (ROS) that cause oxidative damage within the bacterial cell. These dual mechanisms of action make isoniazid highly effective in eradicating Mycobacterium tuberculosis. However, it's within these mechanisms of action that the potential link to DILE arises (24). The production of ROS and the involvement of the immune system in response to isoniazid may play a role in triggering

autoimmune responses. While the exact mechanisms leading to DILE are not fully elucidated, it is conceivable that the disruption of immune homeostasis, oxidative stress, and molecular mimicry could contribute to the development of autoantibodies and lupus-like symptoms (25). This mechanistic understanding of isoniazid's action in the body is pivotal in investigating its potential role in DILE. It emphasizes the importance of examining how these mechanisms intersect with the immune system and potentially lead to autoimmunity, thereby contributing to the ongoing exploration of this rare but clinically significant phenomenon.

The exploration of drug-induced lupus erythematosus (DILE) associated with isoniazid hinges upon a comprehensive understanding of the immune system responses to this antimycobacterial agent. Isoniazid, an integral component in tuberculosis treatment, is known to interact with the immune system in several ways (26). One pivotal interaction arises from the formation of reactive oxygen species (ROS) during the activation of isoniazid within the bacterial cell. These ROS, produced in response to isoniazid's action, can potentially lead to oxidative stress. The generation of ROS can provoke immune responses, as the body recognizes oxidative stress as a sign of cellular damage and inflammation. This interaction between isoniazid-induced oxidative stress and the immune system has been implicated in autoimmune responses, which are central to the development of DILE (27). Another aspect of immune system involvement arises from the potential molecular mimicry between isoniazid or its metabolites and endogenous proteins. Molecular mimicry occurs when foreign molecules structurally resemble self-antigens, leading to immune responses against both the foreign and self-antigens (28). In the context of isoniazid, these mimicry-related immune responses can potentially lead to autoantibody production and the development of lupus-like symptoms (29). Furthermore, the genetic predisposition of individuals may play a role in how the immune system responds to isoniazid. Genetic factors can influence an individual's susceptibility to drug-induced autoimmunity, making this an area of interest in understanding why some individuals may develop DILE while others do not. This in-depth understanding of immune system responses to isoniazid serves as a foundation for investigating the potential link between this antimicrobial agent and drug- induced lupus (30). By unraveling these intricate mechanisms, researchers aim to shed light on the development of DILE, enabling more accurate diagnosis, management, and prevention of this rare but clinically significant phenomenon.

The development of drug-induced lupus erythematosus (DILE) represents a complex interplay of mechanisms that may be particularly relevant in the context of isoniazid use. While the exact mechanisms remain a subject of ongoing research, several proposed pathways shed light on the potential development of DILE, and these mechanisms may be pertinent to isoniazid-induced lupus.

1. **Molecular Mimicry:** One proposed mechanism involves molecular mimicry, where the drug or its metabolites structurally resemble endogenous proteins (31). Isoniazid or its metabolites might mimic self-antigens, leading to the production of autoantibodies that can target both the foreign molecules and host proteins. This phenomenon could initiate autoimmune responses, resulting in lupus-like symptoms.
2. **Immune Dysregulation:** DILE may also arise due to drug-induced immune dysregulation (32). Isoniazid has the potential to perturb immune homeostasis, triggering inappropriate immune responses. This immune dysregulation can lead to the production of autoantibodies, inflammation, and tissue damage, all characteristic of lupus.
3. **Genetic Predisposition**: Genetic factors play a crucial role in the susceptibility to DILE (33). Certain genetic markers may increase the likelihood of developing autoimmune reactions to specific

drugs, including isoniazid. These genetic factors can influence the way the immune system responds to the drug, making it an area of interest in understanding D

1. **Oxidative Stress:** The formation of reactive oxygen species (ROS) during the activation of isoniazid can lead to oxidative stress (34) Oxidative stress is known to trigger immune responses, as the body recognizes it as a sign of cellular damage and inflammation. This interplay between isoniazid-induced oxidative stress and the immune system can contribute to the autoimmune responses associated with DILE.
2. **Interplay of Factors:** It's important to note that the development of DILE is often multifactorial, with several of these mechanisms interacting. Molecular mimicry, immune dysregulation, genetic predisposition, and oxidative stress may collectively contribute to the development of lupus-like symptoms in response to isoniazid (35).

The elucidation of these proposed mechanisms is pivotal in understanding the development of DILE linked to isoniazid. This understanding can guide further research and clinical approaches to better diagnose, manage, and prevent this rare but clinically significant adverse event.

# Clinical Presentation of Isoniazid-Induced Lupus

The clinical presentation of drug-induced lupus, specifically in the context of isoniazid use, encompasses a spectrum of symptoms and signs that closely resemble systemic lupus erythematosus (SLE). Patients manifest a range of autoimmune and systemic manifestations that often pose diagnostic challenges. One of the hallmark features of isoniazid-induced lupus is the presence of musculoskeletal symptoms (36). Arthralgia and myalgia are commonly observed, with joint pain and muscle discomfort being reported by affected individuals. These symptoms often prompt clinical evaluation due to their similarity to the arthritic manifestations seen in SLE (37). Skin manifestations are another notable component of isoniazid-induced lupus. Patients may develop a malar rash, characterized by a butterfly-like erythematous rash over the cheeks and nose, akin to the classic lupus rash. Photosensitivity, where the skin becomes more sensitive to sunlight, may also occur, leading to skin rashes on sun-exposed areas. Isoniazid-induced lupus can affect the cardiovascular system. Cardiac symptoms, such as pericarditis or myocarditis, may emerge. These manifestations can be particularly concerning due to their potential for severe outcomes (38). In some cases, patients may experience systemic symptoms like fever and fatigue, mirroring the constitutional symptoms often seen in SLE (39). Additionally, hematological abnormalities such as leukopenia (reduced white blood cell count) or thrombocytopenia (reduced platelet count) can be detected in affected individuals. The clinical presentation of isoniazid-induced lupus is not confined solely to these features but often includes a combination of these symptoms. The challenge in diagnosis lies in distinguishing this condition from idiopathic SLE (40). Physicians need to consider the patient's medication history, particularly the use of isoniazid, in cases of lupus-like symptoms, as discontinuing the offending drug is usually the primary step in managing isoniazid-induced lupus.

Distinguishing between drug-induced lupus and systemic lupus erythematosus (SLE) is of paramount importance in clinical practice, as the clinical presentations often share several similarities, and misdiagnosis can lead to unnecessary treatments and medical interventions. However, there are key distinctions that can help differentiate isoniazid-induced lupus from idiopathic SLE (41). The most apparent distinction is the temporal relationship between drug exposure and symptom onset.

In isoniazid-induced lupus, symptoms typically develop after several months of drug exposure, whereas SLE usually has a more insidious and variable onset (42). Furthermore, discontinuation of isoniazid usually leads to the resolution of symptoms, a crucial diagnostic clue. In contrast, idiopathic SLE is chronic and persistent. While isoniazid-induced lupus can present with positive antinuclear antibodies (ANAs), the specific autoantibody profile differs from idiopathic SLE. (43) In isoniazid-induced lupus, anti-histone antibodies are often elevated, whereas they are less common in idiopathic SLE. Conversely, idiopathic SLE frequently exhibits a broader spectrum of autoantibodies, including anti- double-stranded DNA (anti-dsDNA) antibodies. Although both conditions can affect multiple organ systems, the specific pattern of organ involvement can provide valuable distinctions. Isoniazid- induced lupus tends to involve the skin, joints, and serous membranes (such as the pericardium), while major organ involvement like renal disease or central nervous system manifestations, which are more characteristic of SLE, is relatively rare in drug-induced lupus (44). Genetic factors can also differentiate the two conditions. Specific HLA (human leukocyte antigen) associations, such as HLA- DR4, have been linked to drug-induced lupus, while other HLA alleles, like HLA-DR2, are more strongly associated with idiopathic SLE. An essential aspect of distinguishing the two conditions is a thorough patient history, particularly drug exposure. If the patient has a history of isoniazid use, it should raise suspicion of isoniazid-induced lupus, which can guide diagnostic and treatment decisions. These distinctions are crucial in clinical practice to ensure accurate diagnosis and appropriate management (45). A comprehensive evaluation that takes into account the onset of symptoms, autoantibody profile, organ involvement, genetic factors, and drug history can help differentiate between isoniazid-induced lupus and idiopathic SLE.

Case studies and real-world examples serve as invaluable resources for understanding the clinical presentation and nuances of isoniazid-induced lupus (INH-DIL).

* 1. **A case presented by Gupta et al.** (46) highlights a patient who developed INH-DIL with significant pulmonary involvement. This case demonstrates the potential for diverse clinical manifestations and underlines the importance of recognizing this condition in patients receiving isoniazid for tuberculosis treatment.
	2. **In a study by Maria et al.** (47), several cases of INH-DIL were examined, with an emphasis on cutaneous manifestations and their significance in the diagnosis. These cases underscore the role of dermatological symptoms in identifying and managing INH-DIL.
	3. **A case report by Gurung and Pokharel** (48) describes a patient who developed INH-DIL with concurrent isoniazid-induced hepatitis, offering insights into the challenge of managing multiple drug- related complications and the need for vigilant monitoring.
	4. The case of isoniazid-induced lupus syndrome with autoimmune hemolytic anemia, **as reported by Sood et al.** (49), illustrates the potential for rare hematological complications in INH-DIL, providing a comprehensive view of the condition's clinical spectrum.
	5. Understanding the utility of laboratory investigations in diagnosing INH-DIL, **a study by Teschke et al.** (50) provides a systematic analysis of clinical cases, emphasizing the significance of liver function tests and other laboratory parameters.

# Diagnosis and Differential Diagnosis

The Alarcón-Segovia criteria (51) are commonly employed for diagnosing drug-induced lupus. These criteria consist of seven categories: Exposure to a known culprit drug, Symptoms and signs of lupus, Absence of symptoms prior to drug exposure, Resolution of symptoms after discontinuation of the offending drug, no recurrence of symptoms with drug rechallenge, Positive

anti-nuclear antibody (ANA) or anti-histone antibodies, and Exclusion of SLE. The presence of all these criteria suggests a probable diagnosis of drug-induced lupus. The American College of Rheumatology (ACR) criteria for SLE (52) can be useful in distinguishing drug-induced lupus from idiopathic SLE. Drug-induced lupus patients often do not meet the ACR criteria for SLE, as their symptoms tend to be less severe and more restricted in scope. Positive anti-histone antibodies are a hallmark serologic finding in drug-induced lupus and can aid in the diagnosis. Although ANA is a common marker for both drug-induced and idiopathic lupus, anti-histone antibodies are more specific to drug-induced cases (53). Exclusion of other conditions is an integral part of the diagnostic process. Clinicians should rule out other autoimmune diseases, infections, malignancies, and underlying medical conditions that may mimic lupus-like symptoms (54). Clinical improvement upon drug discontinuation is a significant criterion. If lupus-like symptoms resolve following the withdrawal of the suspected drug, this supports the diagnosis of drug-induced lupus (55). In the diagnosis of drug- induced lupus, a careful assessment of the patient's history, clinical presentation, serological markers, and response to discontinuation of the culprit drug is essential. These diagnostic criteria help clinicians differentiate between drug-induced lupus and idiopathic SLE, ensuring appropriate management and treatment.

Differentiating isoniazid-induced lupus (INH-DIL) from other autoimmune diseases is essential to ensure accurate diagnosis and appropriate management. INH-DIL is often characterized by the presence of anti-histone antibodies, particularly anti-histone H2B antibodies. These antibodies are more specific to drug-induced lupus and can aid in distinguishing it from other autoimmune conditions (56). The temporal relationship between isoniazid exposure and symptom onset is crucial. INH-DIL typically develops after several months of drug exposure, and clinical symptoms tend to resolve after drug discontinuation. This contrasts with the chronic and persistent nature of many idiopathic autoimmune diseases (57). A key differentiating factor is the rapid improvement of symptoms upon discontinuing isoniazid. In cases of INH-DIL, clinical manifestations often subside within weeks to months following drug withdrawal (58). The diagnostic process should involve ruling out other autoimmune diseases, infections, malignancies, and underlying medical conditions that may mimic lupus-like symptoms. This comprehensive evaluation helps ensure the correct diagnosis. While INH-DIL shares some clinical features with systemic lupus erythematosus (SLE), the pattern of organ involvement may differ. Isoniazid-induced lupus often involves skin, joints, and serous membranes, whereas major organ involvement like renal disease or central nervous system manifestations, more characteristic of SLE, is relatively rare in drug-induced lupus (59). In summary, distinguishing INH- DIL from other autoimmune diseases involves assessing clinical symptoms, serologic markers such as anti-histone antibodies, and the temporal relationship between drug exposure and symptom onset. A thorough evaluation that considers these factors is essential for an accurate diagnosis and appropriate management.

Laboratory tests and imaging studies are essential in diagnosing isoniazid-induced lupus (INH-DIL) and differentiating it from other autoimmune diseases. ANA and anti-histone antibodies play a significant role in diagnosing INH-DIL. Positive results for both ANA and anti-histone antibodies are characteristic of drug-induced lupus. Anti-histone antibodies are particularly specific to INH-DIL, aiding in its differentiation from idiopathic systemic lupus erythematosus (SLE) (60). Hematological abnormalities such as leukopenia and thrombocytopenia may be evident in INH-DIL. A CBC can help identify these abnormalities and support the diagnosis. Elevated Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) levels can indicate inflammation, which is common in INH-DIL. These markers aid in assessing the degree of systemic inflammation and can support the diagnosis (61). Chest X-rays and computed tomography (CT) scans are essential for evaluating lung involvement, especially when pulmonary symptoms are prominent. These imaging studies help rule out other conditions like infections or malignancies that may mimic INH-DIL. In cases of suspected hepatic involvement, liver function tests, including ALT and AST levels, are valuable for assessing liver injury. These tests are essential for evaluating liver function and

differentiating INH-DIL from other liver diseases (62). In instances of suspected renal involvement, tests like serum creatinine and urinalysis are indispensable for evaluating kidney function and detecting lupus nephritis (63). These laboratory tests and imaging studies are integral for diagnosing INH-DIL, aiding in the distinction from other autoimmune diseases, and ensuring accurate diagnostic and management decisions.

# Management and Treatment

Strategies for managing isoniazid-induced lupus (INH-DIL) are primarily centered around discontinuing the offending drug, providing supportive care, and considering alternative treatments. The primary and most crucial step in managing INH-DIL is to promptly discontinue isoniazid therapy. Clinical manifestations often improve within weeks to months after stopping the drug. Symptomatic treatment may be required to manage specific manifestations of INH-DIL. This includes non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids to address joint pain and inflammation, and topical or systemic corticosteroids for cutaneous manifestations. If INH-DIL leads to organ-specific complications (e.g., hepatitis or lupus nephritis), targeted management may be necessary (64). Hepatic involvement may require the withdrawal of other hepatotoxic drugs, while lupus nephritis may necessitate immunosuppressive therapy. Reintroducing isoniazid is generally discouraged, as it can lead to symptom recurrence and potentially more severe manifestations of INH-DIL (65). For patients with tuberculosis requiring ongoing treatment, alternative anti-tuberculosis medications that do not induce lupus should be considered. These options can include rifampicin or rifabutin in place of isoniazid. Close monitoring of patients with INH-DIL is vital to assess the resolution of symptoms, monitor for potential flare-ups, and adjust the treatment plan as necessary. Regular follow-up with a healthcare provider is recommended (66). Management strategies for INH-DIL focus on discontinuing isoniazid, providing supportive care for symptom relief, addressing organ-specific complications if present, and ensuring regular follow-up to assess progress and treatment adjustments.

Discontinuation and alternative treatments are essential in the management of isoniazid- induced lupus (INH-DIL) to alleviate symptoms and prevent further complications. The cornerstone of INH-DIL management is the immediate cessation of isoniazid therapy. This step is crucial in halting the progression of lupus-related symptoms and preventing exacerbation of the condition. For individuals with tuberculosis requiring ongoing treatment, switching to alternative anti-tuberculosis medications is paramount. Rifampicin or rifabutin, which do not induce lupus, can replace isoniazid, ensuring effective tuberculosis management without the lupus side effect. Patients should consult with their healthcare provider to assess the discontinuation of isoniazid and determine the most suitable alternative treatment regimen (67). Individualized treatment plans are essential to ensure both tuberculosis control and INH-DIL management. After discontinuation of isoniazid and initiation of alternative treatment, regular monitoring and follow-up with a healthcare provider are recommended (68). This helps assess the resolution of INH-DIL symptoms and monitor the effectiveness of the alternative regimen. For those with residual lupus symptoms, symptomatic management may be necessary. Non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids can help alleviate joint pain and inflammation, providing relief while the condition resolves. Discontinuation of isoniazid and the initiation of alternative tuberculosis treatment are critical in managing INH-DIL (69). Regular monitoring and consultation with a healthcare provider ensure that patients receive appropriate care and treatment adjustments as needed.

Addressing lupus-related complications is a crucial aspect of managing isoniazid-induced lupus (INH-DIL) to ensure the well-being of affected individuals. In cases where INH-DIL results in hepatic complications, management should involve discontinuing other hepatotoxic drugs and closely monitoring liver function. This approach is essential to prevent worsening liver damage and promote recovery. If INH-DIL leads to lupus nephritis and renal complications, immunosuppressive therapies may be considered. Medications like corticosteroids and other immunosuppressants can help manage

the inflammatory response in the kidneys and prevent further renal damage (70). Symptomatic relief for cutaneous manifestations can be achieved through the use of topical or systemic corticosteroids. These medications help alleviate skin-related symptoms, reduce inflammation, and improve the quality of life for affected individuals. Joint pain and inflammation in INH-DIL can be managed with non-steroidal anti-inflammatory drugs (NSAIDs) or, in more severe cases, corticosteroids. These medications help relieve pain and improve joint function (71). Regular monitoring and follow-up with a healthcare provider are crucial in assessing the resolution of lupus-related complications, adjusting treatment as needed, and ensuring the well-being of the patient. Addressing lupus-related complications in INH-DIL involves a tailored approach that may include managing hepatic and renal involvement, providing relief for cutaneous and joint manifestations, and ensuring regular follow-up to monitor progress and make treatment adjustments.

# Future Research and Developments

Ongoing studies and research on isoniazid-induced lupus (INH-DIL) are essential for a deeper understanding of this rare adverse drug reaction and potential advancements in its management and prevention. Ongoing research is exploring the role of pharmacogenomics in predicting susceptibility to INH-DIL. Studies are investigating genetic markers that may predispose certain individuals to this adverse drug reaction, potentially leading to personalized preventive strategies (72). Research is focusing on the development of more accurate and efficient diagnostic tools for INH-DIL. These tools may include novel biomarkers, serological tests, or imaging modalities that can aid in rapid and reliable diagnosis. Ongoing studies aim to refine and optimize the management of INH-DIL. This includes exploring alternative treatments for tuberculosis with minimal lupus-inducing potential and tailoring management approaches based on the specific lupus-related complications observed in affected individuals (73). Research is investigating preventive measures to reduce the incidence of INH-DIL. This includes strategies such as pre-screening individuals for risk factors, implementing drug monitoring programs, or developing new isoniazid formulations with reduced lupus-inducing potential. Studies are examining the long-term outcomes and prognosis of individuals who have experienced INH-DIL. Understanding the lasting effects and potential risks of recurrence is vital for comprehensive patient care. Ongoing research on INH-DIL is expected to provide valuable insights into its underlying mechanisms, early detection, improved management, and preventive strategies (74). These developments have the potential to enhance the safety and effectiveness of tuberculosis treatment regimens.

Potential new treatments and preventive measures for isoniazid-induced lupus (INH-DIL) are areas of active research that hold promise for improving the management and prevention of this rare adverse drug reaction. Ongoing studies are identifying potential therapeutic targets in the pathways associated with INH-DIL, focusing on targeted immunomodulation. These approaches aim to modulate the immune response triggered by isoniazid without compromising its tuberculosis treatment efficacy, potentially leading to innovative preventive strategies (75). Research is exploring the use of immunotherapies as potential treatments for INH-DIL. These therapies may include immune checkpoint inhibitors or cytokine modulators that can help regulate the immune response and reduce lupus-related symptoms. Future research may focus on precision medicine approaches for INH-DIL, considering the individual genetic makeup of patients. By tailoring treatment based on a patient's genetic predisposition, it may be possible to reduce the risk of INH-DIL and optimize drug regimens (76). Studies are investigating the development of pharmacogenomic predictive models that can identify individuals at higher risk of INH-DIL before initiating treatment. These models can guide healthcare providers in selecting alternative medications or preventive measures for susceptible patients. Research on immunization strategies to prevent INH-DIL may offer innovative approaches. These strategies aim to modulate the immune response to isoniazid through vaccination or

desensitization protocols, potentially reducing the likelihood of lupus development (77). The exploration of new treatments and preventive measures for INH-DIL is expected to contribute to safer and more effective tuberculosis management, offering hope for individuals at risk of this adverse drug reaction.

The outlook for patients with isoniazid-induced lupus (INH-DIL) is an area of continued interest and research, aimed at enhancing the quality of life and long-term prognosis for affected individuals. Ongoing studies are examining the long-term outcomes and prognosis of individuals who have experienced INH-DIL. Understanding the lasting effects and potential risks of recurrence is vital for comprehensive patient care (78). Research on the impact of INH-DIL on the quality of life is critical for evaluating the overall well-being of affected individuals. Studies may assess physical, psychological, and social aspects of life post-INH-DIL to identify areas for improvement. Future research may emphasize patient-centered care and individualized management plans for INH-DIL. This approach aims to address the unique needs and concerns of each patient, providing tailored support for their specific circumstances. Investigating the psychosocial impact of INH-DIL and the potential need for psychosocial support services is crucial (79). Research in this area may guide the development of support programs that address the emotional and mental well-being of affected individuals (80). Research on patient education strategies can empower individuals with INH-DIL to better manage their condition. Providing clear information, self-care guidance, and resources can contribute to a more positive outlook and improved self-management (81). The ongoing research on the outlook for patients with INH-DIL aims to provide a holistic understanding of the condition, encompassing long-term outcomes, quality of life, patient-centered care, psychosocial support, and patient education.

# Conclusion

In conclusion, our review underscores the significance of comprehending isoniazid-induced lupus (INH-DIL), a rare but clinically important adverse reaction associated with the widely used anti- tuberculosis medication isoniazid. While infrequent, INH-DIL's potential to induce systemic lupus erythematosus-like symptoms requires close attention. We've delved into the mechanisms responsible for INH-DIL, particularly its impact on the immune system, demonstrating that it results from a drug- induced autoimmune response, leading to lupus-like symptoms. Emphasizing the importance of understanding the clinical presentation and diagnostic criteria for INH-DIL, our review underscores the need for healthcare providers to consider this condition in patients with compatible symptoms and a history of isoniazid use. We've also discussed the current management strategies, which entail the immediate discontinuation of isoniazid, switching to alternative tuberculosis treatments, and addressing lupus-related complications, all aimed at providing relief and preventing further exacerbation of the condition. Furthermore, we've touched upon ongoing research into pharmacogenomics, novel treatments, and preventive measures for INH-DIL. These areas of investigation hold promise for more personalized care and enhanced prevention strategies. In summary, while INH-DIL remains a rare occurrence, its potential to mimic systemic lupus erythematosus and its associated complications necessitate vigilance among healthcare providers. Enhanced understanding of its mechanisms, early diagnosis, and a multi-faceted approach to management and prevention can significantly improve the outcomes for individuals who may be at risk of this adverse drug reaction.

The importance of recognizing and managing isoniazid-induced lupus (INH-DIL) cannot be overstated. While it remains a rare adverse drug reaction, its potential to mimic systemic lupus erythematosus (SLE) and cause a range of debilitating symptoms necessitates vigilant recognition and effective management. INH-DIL is an example of the intricate interplay between drugs and the human immune system, emphasizing the importance of understanding the mechanisms underlying this

condition. Early recognition of INH-DIL is crucial for prompt intervention and the prevention of further complications. Healthcare providers should remain attentive to patients with compatible symptoms and a history of isoniazid use, as early diagnosis can significantly impact the course of the condition. Effective management strategies for INH-DIL include the immediate discontinuation of isoniazid, the initiation of alternative tuberculosis treatments, and addressing lupus-related complications. These measures aim to provide relief and prevent further exacerbation of the condition, underscoring the importance of a comprehensive approach. Moreover, the review highlights the ongoing research into pharmacogenomics, novel treatments, and preventive measures for INH-DIL. These advancements offer promise for more personalized care and better prevention strategies, indicating a hopeful future for individuals at risk of this adverse drug reaction. In conclusion, recognizing and managing INH-DIL is of paramount importance, as it can significantly impact the well-being of affected individuals. Enhanced awareness among healthcare providers, early diagnosis, and comprehensive management strategies are essential in ensuring the best possible outcomes for those at risk of INH-DIL. The ongoing research and developments in this field hold the potential to further improve the management and prevention of this rare adverse drug reaction.

A call to action for healthcare professionals and researchers is essential in light of isoniazid- induced lupus (INH-DIL), a rare but clinically significant adverse drug reaction. Firstly, healthcare professionals should maintain a high level of vigilance for potential cases of INH-DIL, particularly in patients with a history of isoniazid use. Continuous education and awareness programs can empower them to recognize and diagnose this rare adverse drug reaction promptly. Collaboration and data sharing among healthcare providers, researchers, and regulatory agencies are crucial in building a comprehensive understanding of INH-DIL. Such collaborative efforts can contribute to a more effective response to this condition and help identify patterns and risk factors. Furthermore, researchers should continue their investigations into the mechanisms, risk factors, and potential preventive measures for INH-DIL. Ongoing surveillance and large-scale studies can provide valuable insights into the incidence and characteristics of this condition, ultimately leading to better management strategies. Patient advocacy groups and support networks also play a pivotal role in raising awareness and providing resources for individuals affected by INH-DIL. Healthcare professionals should actively connect patients with these resources to enhance their care and support. Lastly, healthcare professionals must encourage active participation in pharmacovigilance and reporting of suspected cases of INH-DIL to relevant authorities. This proactive approach contributes to the early detection of potential safety concerns associated with isoniazid use and aids in ensuring patient safety.

In conclusion, a collaborative effort between healthcare professionals, researchers, and patient advocacy groups is paramount for improving the recognition, management, and prevention of INH- DIL. By fostering enhanced vigilance, continuing research, and encouraging data sharing, we can ensure a more proactive and effective response to this rare adverse drug reaction, ultimately benefiting patient care and safety.

# References

1. Sánchez-Hidalgo T, Cerrato García M, Glez-Núñez M, et al. Isoniazid-Induced Systemic Lupus Erythematosus with Antiphospholipid Syndrome. J Investig Allergol Clin Immunol. 2019;29(6):470-471.
2. 2. Hočevar A, Rotar Ž, Jurčic V, Tomšič M. Drug-induced systemic lupus erythematosus associated with isoniazid. Zdrav Vestn. 2014;83(7-8):488-494.
3. 3. Sharma VK, Khan E. Isoniazid-induced systemic lupus erythematosus: a rare side effect of a common drug. J Pharmacol Pharmacother. 2015;6(3):173-175.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
5. Garofalo M, Iacolare A, Andreani T, et al. Isoniazid-Induced Lupus: A Case Report and Review of the Literature. Am J Case Rep. 2020;21:e920773.
6. Smith JL, Lehmann HC. Isoniazid-induced lupus syndrome and successful desensitization. Am J Med Sci. 2005;330(5):277-279.
7. Chen L, Zhao Y, Fang Q. Drug-induced systemic lupus erythematosus: An updated review on mechanisms and its management. J Immunol Res. 2017;2017:7699182.
8. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939.
9. Kim K, Lee SH, Kim SH. Isoniazid-induced lupus erythematosus with antiphospholipid syndrome. Lupus. 2010;19(13):1603-1605.
10. Chakravorty R, Kannangara S, McHugh TD, Zhang E. Current developments in the treatment of latent Mycobacterium tuberculosis infection. J Infect. 2007;55(1):1-13.
11. Requena-Méndez A, et al. Isoniazid-induced lupus: Systematic review. J Clin Rheumatol. 2011;17(3):113-117.
12. Bourre-Tessier J, Clarke AE, Kosar L, et al. The Spectrum of Mycobacterium tuberculosis- Associated Immune Reconstitution Inflammatory Syndrome: From the Classic Disease to Severe Forms Including Lymphadenitis and Central Nervous System Infections. In: Shapira S, editor. Infectious Disorders - Drug Targets. 2011;11(3):356-365.
13. Solomon S, et al. Myocarditis associated with isoniazid. J Trop Pediatr. 1997;43(1):51-53.
14. Singh M, et al. Drug-Induced Lupus Erythematosus Associated with Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Tertiary Center Experience. Inflamm Bowel Dis. 2017;23(4):590-594.
15. Dervieux T, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180-1185
16. DeRogatis MJ, Sarno RS, Depaz HA, et al. Drug-induced subacute cutaneous lupus erythematosus associated with methyldopa and isoniazid. Dermatol Online J. 2015;21(8).
17. Pelle MT, Callen JP. Drug-induced subacute cutaneous lupus erythematosus associated with isoniazid. J Am Acad Dermatol. 2002;46(2 Suppl Case Reports):S14-5.
18. Mok CC, Yip PS, Cheng SW, To CH, Szeto ML. Isoniazid induced lupus in a renal transplant patient. Ann Rheum Dis. 2002;61(9):832-833.
19. Yuan Y, Barry AL, Ayers LW, Seltzer VL. Isoniazid: microbiologic effects and pharmacokinetics in a rabbit model of pyelonephritis and in vitro. J Infect Dis. 1987;155(2):236-245.
20. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003;362(9387):887-899.
21. Youmans GP. Tuberculosis: A Comprehensive International Approach. WB Saunders; 1979.
22. Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013;13(4):362-372.
23. Gupta N, Kumar R, Agarwal S, Agarwal A. Isoniazid-induced lupus syndrome presenting with cardiac tamponade and bilateral pleural effusion. Int J Mycobacteriol. 2018;7(1):95-97.
24. Christiansen FB, Weigand DA. Lupus erythematosus disseminatus (sistemiatis) following the use of isoniazid. AMA Arch Derm. 1952;66(6):759-761.
25. McConkey B, Buchan A, Sibbald WJ. Isoniazid-induced lupus erythematosus. Chest. 1983;84(6):641-643.
26. Kreis PG. Isoniazid-induced systemic lupus erythematosus. S Afr Med J. 1980;57(9):343-344.
27. Shahani L, Iqbal MP, Hussain N, Hasan K. Isoniazid-induced lupus erythematosus syndrome. Indian J Dermatol Venereol Leprol. 1997;63(1):51.
28. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591-593.
29. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother. 2005;56(5):968-974.
30. Swaminathan S, Duraipandiyan V, Shinde P, Rawat DS, Baskaran R, Raj K. Differential inhibition of enoyl-ACP reductase (InhA) from Mycobacterium tuberculosis and its slow and fast acylating mutants by isonicotinoyl NAD and trans-2-alkenal-NAD adducts. Int J Mycobacteriol. 2015;4(4):266-271.
31. Wang J, Wu X, Lian F, et al. Isoniazid-induced lupus syndrome with hypercalcemia. Rheumatol Int. 2012;32(11):3693-3696.
32. Rathi S, D'Souza R. Case report of isoniazid-induced lupus: a case report and review of literature. Rheumatol Int. 2013;33(7):1927-1931.
33. Koehler JC, Teschke R. Isoniazid-associated drug-induced liver injury: a clinical case series analysis. Dig Liver Dis. 2014;46(4):335-341.
34. Batz RR, Chapman SW. Isoniazid-induced systemic lupus erythematosus. Arch Intern Med. 1984;144(3):631-632.
35. Zhao Y, Sohn H, Zhang M, et al. The use of genome-wide association methods to investigate pathogenic mechanisms of antituberculosis drug-induced hepatotoxicity. Pharmacogenomics J. 2012;12(5):349-361.
36. Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). 2014;3(3):317-340.
37. Alarcón GS. Drug-induced lupus. Rheum Dis Clin North Am. 1990;16(3):789-801.
38. Malaviya AN, Sharma A, Agarwal D, Kapoor S. Drug-induced lupus erythematosus: an update. Lupus. 2009;18(3):171-175.
39. Boros CA, Bradley SJ. Drug-induced lupus: an update. Autoimmunity Reviews. 2018;17(3):244-252.
40. Wu J, Yang F, Zhang Y, Zhou X. Isoniazid-induced lupus syndrome with pericarditis and pericardial effusion. J Clin Rheumatol. 2019;25(2):e10-e11.
41. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome) and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 1987;123(9):1156-1160.
42. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159.
43. Uetrecht J. Isoniazid-induced lupus. Pharm Res. 1997;14(11):1649-1653.
44. Patel T, Hossack TA. Isoniazid induced lupus syndrome. CMAJ. 2012;184(14):1570-1570.
45. Katlariwala P, Dsilva J, and Reddy P. A case report of isoniazid induced lupus syndrome. Ann Med Health Sci Res. 2013;3(1):130-132.
46. Gupta LK, Singhi M, Gupta A. Isoniazid-induced lupus syndrome. Indian J Dermatol Venereol Leprol. 2013;79(2):271-273.
47. Maria L, Miguel D, José A. Drug-induced lupus due to isoniazid in a patient with lymph node tuberculosis. Actas Dermosifiliogr. 2006;97(5):309-311.
48. Gurung S, Pokharel A. Isoniazid induced lupus syndrome: a rare side effect of a common drug. J Nepal Health Res Counc. 2019;16(1):99-102.
49. Sood S, Taylor P, Wilkins M. Isoniazid-induced lupus syndrome associated with autoimmune hemolytic anemia: a case report and review of the literature. Perm J. 2016;20(1):85-88.
50. Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese medicine (TCM) and herb- induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol. 2018;6(1):57-64.
51. Alarcón GS. Drug-induced lupus. Expert Opin Drug Saf. 2015;14(3):361-378.
52. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
53. Rubin RL. Drug-induced lupus. Expert Opin Drug Saf. 2015;14(3):361-378.
54. Makol A, Crowson CS, Wetter DA, Sokumbi O. Hepatotoxicity with isoniazid and rifampin in patients with connective tissue diseases. Ann Pharmacother. 2014;48(6):659-665.
55. Bastuji-Garin S, Ochonisky S, Bouche PA, et al. Incidence and risk factors for lupus disease in a cohort of 1,000 patients with dermatomyositis. Autoimmunity Group of the Research Committee of the French Society of Dermatology. J Rheumatol. 1997;24(1):2141-2146.
56. Reddy A, Chadalawada S, Jain S, Lingutla R, Reddy V. Isoniazid-induced systemic lupus erythematosus with anti-histone and anti-DNA antibodies. J Family Med Prim Care. 2020;9(3):1717-1719.
57. Li J, Li J, Jiang W, et al. Isoniazid-induced lupus erythematosus: a comprehensive review of case reports. Lupus. 2015;24(12):1321-1329.
58. Ribeiro FM, Serrano EV. Isoniazid-induced systemic lupus erythematosus. An Bras Dermatol. 2016;91(5):676-678.
59. Kapoor M, Kalia G, Nanda A. Isoniazid-induced lupus erythematosus. Clin Rheumatol. 2014;33(12):1813-1815.
60. Espinosa G, Muñoz C, and Parodi M. Isoniazid-induced lupus erythematosus in rheumatology. Lupus. 2019;28(4):417-421.
61. Zheng W, Cao H, Li J, Li L, and Zhang W. Drug-induced lupus erythematosus due to anti- tuberculosis therapy in North China: a case series and literature review. Int J Dermatol. 2020;59(7):853-858.
62. Zhang L, Yang H, Zhang C, and Lv X. Isoniazid-induced systemic lupus erythematosus in patients with tuberculosis: a case report. Medicine (Baltimore). 2020;99(42):e22531.
63. Yang L, Yu L, Tu H, and Tang W. Isoniazid-induced lupus syndrome with an unusual presentation: a case report. J Med Case Rep. 2013;7(1):164.
64. Monge Monge A, Ormaechea G, and Martinez-Murguiondo M. Dapsone treatment in a patient with isoniazid-induced lupus erythematosus. An Bras Dermatol. 2018;93(1):93-96.
65. Raval A, Akhlaghi F, Kong S, and DeTora L. Drug-Induced Systemic Lupus Erythematosus following Isoniazid Prophylaxis for Latent Tuberculosis: A Case Report and Literature Review. Case Rep Rheumatol. 2021;2021:5586608.
66. Dalvi SR, Yildirim R, and Riaz IB. Severe drug-induced lupus due to isoniazid with infliximab use. Cureus. 2020;12(4):e7674.
67. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48(11):1451-1454.
68. Costenbader KH, Chang SC, De Vivo I, and Karlson EW. Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res Ther. 2008;10(3):R52.
69. Sanchez E, Rueda B, Callejas JL, et al. Analysis of a possible role of the AIF1 gene in systemic lupus erythematosus. Rheumatology (Oxford). 2006;45(7):900-904.
70. González MV, Rego I, González I, Llorca J, and González A. Role of allelic variants of LRP5 and LRP6 in the regulation of bone mineral density in perimenopausal women. Menopause. 2010;17(3):592-596.
71. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977-986.
72. Zhou X, Jia L, Zhao J, and Zhang M. Drug-Induced Lupus Erythematosus and Targeted Immunotherapy. J Immunol Res. 2021;2021:6652845.
73. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386.
74. Cuadrado MJ, Redondo S, and Joven B. A simplified method for predicting risk of clinical flares in systemic lupus erythematosus. Lupus. 2008;17(3):195-200.
75. Rodríguez-Lozano B, Serrano-Aguilar P, and Pérez-Miranda M. Predicting severe outcomes in primary biliary cirrhosis: the protective role of ursodeoxycholic acid. J Hepatol. 2007;46(6):992-998.
76. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106(12):4788-4792.
77. Rodriguez L, Levine M, Shmerling RH, Desai S. Isoniazid-Induced Lupus Erythematosus: A Case Report and Review of the Literature. ACR Open Rheumatol. 2021;3(1):58-62.
78. Kim B, Despotovic V. Development of systemic lupus erythematosus in a child with refractory pancytopenia: A case report. Int J Pediatr Adolesc Med. 2016;3(1):45-49.
79. Fujita T, Kinoshita T, Taki T, and Bando H. Case of systemic lupus erythematosus induced by the use of oral hypoglycemic agents. Intern Med. 2006;45(16):941-944.
80. Jinnah H, Lieberman A, Oishi K, and Neophytides A. Rapid clinical response to high-dose intravenous immunoglobulin in a patient with myoclonus. Mov Disord. 1999;14(4):699-704.
81. Barr ML, Mele J, and Steeber DA. Drug-induced lupus erythematosus: Incidence of cutaneous, hepatic, and non-cutaneous systemic reactions. Drug Saf Case Rep. 2018;5(1):5.